Bioferon (interferon alpha 2b) / Biosidus - LARVOL DELTA

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=5 | Terminated | Sponsor: Roswell Park Cancer Institute | Trial completion date: Dec 2025 ➔ Jun 2025 | Active, not recruiting ➔ Terminated; Funding ended

Trial completion date • Trial termination • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=5 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Active, not recruiting | N=15 ➔ 5 | Trial completion date: Jun 2025 ➔ Dec 2025

Enrollment change • Enrollment closed • Trial completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Dec 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2025 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jun 2025 ➔ Dec 2025 | Initiation date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jul 2027 ➔ Jun 2025 | Trial primary completion date: Jul 2026 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Apr 2027 ➔ Jul 2027 | Trial primary completion date: Apr 2026 ➔ Jul 2026

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute

Metastases • New P1/2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer